Just days before one of biotech's busiest weeks, a quartet of IPO filings by Menlo Therapeutics Inc., Restorbio Inc., Armo Biosciences Inc. and Solid Biosciences LLC are outlining the case for investing millions of dollars in the development of new therapies.